Opinion on Central Nervous System in Australia

Published within

|« « | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Merck Serono: cladribine's failure is a big setback for the company, not MS patients

Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.

Published By Datamonitor
 22 Jun 2011
CommentWire
CommentWire

Mundipharma: OxyContin CR patent challenge threatens Australian market share

In an attempt to launch its own generic controlled-release oxycodone product, Spirit Pharmaceuticals has claimed that Mundipharma's Australian patent for OxyContin is invalid due to a lack of supporting clinical trials. While Mundipharma has recovered from similar challenges in the US, OxyContin revenues will be significantly harmed if Spirit's claim is upheld.

Published By Datamonitor
 24 Aug 2010
CommentWire
CommentWire

Prana: Alzheimer drug shows promise

Prana's [PRAN] positive pilot trial results offer hope for millions of Alzheimer's sufferers, whose treatments are limited by symptomatic effect only. PBT-1 is becoming an increasingly attractive in-licensing opportunity and, assuming safety and disease modifying ability is shown in large trials, it has potential to grab a large share of this multi-billion dollar market.

Published By Datamonitor
 19 Dec 2003

|« « | 1 | » »|

Help

Close
No help is available.